Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

CpG Oligonucleotides Treatment to Prevent Chemotherapy-Induced Pulmonary Toxicity

Posted Apr 03 2013 8:00pm

Description of Invention:
Bleomycin (BLM) is a chemotherapy agent used to treat multiple types of cancer, but its side effects are life threatening for some patients. About 20% of patients undergoing BLM chemotherapy develop interstitial pneumonitis which may develop to life threatening fibrosis. In such cases, BLM chemotherapy cannot be continued.

This invention identifies a method of pre-treatment using immunostimulatory CpG Oligonucleotide (ODN) molecules to prevent chemotherapy-induced pulmonary toxicity. Administration of certain ODN molecules induces inflammation via stimulation of inflammatory genes (Toll-like receptor 9/TLR9). This stimulation is subsequently down-regulated. This technology makes use of this counter regulatory mechanism to reduce the side effects of chemotherapy agents, such as BML. A properly timed pre-administration of ODN molecules, prior to BML therapy, prevents the lethal side effect of BLM-induced pulmonary inflammation and down-regulates promoters of BLM toxicity (IL-17A and TGF-beta1). Because toxicity from pulmonary inflammation is a side effect limiting use of many chemotherapeutic agents and ODN molecules are relatively inexpensive and have a favorable safety profile, this technology may be useful to improve treatment protocols for many chemotherapy agents.

Applications:
Therapeutic to reduce harmful side effects of pulmonary inflammation caused by chemotherapy.

Advantages:
  • Pulmonary toxicity during chemotherapy is dangerous side effect, this technology uses ODN molecules that are relatively inexpensive and have a favorable safety profile to reduce this side effect.
  • This technology may increase the safety and availability of many chemotherapy treatments.


Development Status:
  • Early-stage
  • In vivo data available (animal)


Inventors:
Dennis M Klinman (NCI)
Takeshi Kinjo (NCI)


Patent Status:
HHS, Reference No. E-077-2012/0
US, Application No. 61/643,088 filed 04 May 2012


Relevant Publication:
  1. Kinjo T, et al. [ PMID 22708497 ]


Collaborative Research Opportunity:
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize CpG oligonucleotides for use to down-modulate inflammatory reactions. For collaboration opportunities, please contact John D. Hewes, Ph.D. at hewesj@mail.nih.gov .


For Licensing Information Please Contact:
Edward (Tedd) Fenn
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: fennea@mail.nih.gov
Phone: 301-435-5031
Fax: 301-402-0220


Ref No: 2549

Updated: 04/2013

Post a comment
Write a comment:

Related Searches